Advertisement

Adding a Kinase to Pembrolizumab May Increase CLL Treatment Efficacy

Jul 16, 2024

REFERENCES & ADDITIONAL READING

Wang Y, et al. Efficacy of pembrolizumab monotherapy in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL). J Clin Oncol. 42, 2024 (suppl 16; abstr 7050). doi:1200/JCO.2024.42.16_suppl.7050

ABOUT THE EXPERTS

  • Hematologist and Oncologist
    Assistant Professor of Medicine
    Assistant Professor of Oncology
    Mayo Clinic

     

    Yucai Wang, MD, PhD, has indicated to Physician’s Weekly that he has financial interests with Merck; Kite, a Gilead Company; AstraZeneca; BeiGene; Genmab; Incyte; Innocare; Janssen; Lilly; Loxo; TG Therapeutics; Genentech; MorphoSys; and Novartis.

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement